Bone Biologics Corporation (BBLG)

US — Healthcare Sector
Peers: TIVC  TLIS  BJDX  HSCS  NUWE  NTRB  IMMX  KTTA  BFRI 

Automate Your Wheel Strategy on BBLG

With Tiblio's Option Bot, you can configure your own wheel strategy including BBLG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BBLG
  • Rev/Share 0.0
  • Book/Share 0.9145
  • PB 3.2148
  • Debt/Equity 0.0
  • CurrentRatio 12.5899
  • ROIC -1.8127

 

  • MktCap 3936689.0
  • FreeCF/Share -1.1774
  • PFCF -1.0504
  • PE -2.1947
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.3024

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Why Is Bone Biologics Stock Surging On Friday?
BBLG
Published: June 27, 2025 by: Benzinga
Sentiment: Positive

Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.

Read More
image for news Why Is Bone Biologics Stock Surging On Friday?
Bone Biologics Announces Pricing of $5.0 Million Public Offering
BBLG
Published: June 27, 2025 by: Business Wire
Sentiment: Neutral

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a.

Read More
image for news Bone Biologics Announces Pricing of $5.0 Million Public Offering
Bone Biologics Announces 1-for-6 Reverse Stock Split
BBLG
Published: June 06, 2025 by: Business Wire
Sentiment: Neutral

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,”.

Read More
image for news Bone Biologics Announces 1-for-6 Reverse Stock Split

About Bone Biologics Corporation (BBLG)

  • IPO Date 2021-10-13
  • Website https://www.bonebiologics.com
  • Industry Medical - Devices
  • CEO Jeffrey Frelick
  • Employees 2
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.